

#

3D invitro ECM, Tumor microenvironment, RAS A003

A

ApoA2-isoforms A081

acinar re-differentiation A092

Acquired resistance, Allele-specific signaling B060

Acquired resistance, Patient-derived organoids, c-Myc B058

Actincytoskeleton dynamics B006

adaptive resistance B049, B059

Adaptive resistance to KRAS inhibitors B057

Adoptive cell therapy B086

adoptive cell therapy, Phase 1 clinical trial A126

AI A099

AI-assisted digital pathology B027

Alcea rosea B065

Allogeneic cell therapy B100

ALPP/ALPPL2 surface targets A041

Angiogenesis A014

Annamycin A121

antibody secreting cell B077

antibody-drug conjugated A041

Antigen presentation B089

Apoptosis Triggers B144

ARID1A B143

Artificial intelligence A082, A123, B134

Artificial Intelligence A067, A095

autophagy A047

Autophagy A111, A112

Azenosertib A127


B

B Cells A018


Basal-like and classical A026

basal-squamous pancreas cancer A053


Basal-squamous PDAC A031




Bayesian statistics	A104
BET, CDK9	B127
bile acids	B088
bioinformatics	A064
Biomarker	A028, A076, A084
Biomarker detection	A042
biomarker validation	A109
Biomarker validation	A105
Biomarkers	A077
biometric data	A098
Biomolecular condensate	A059
BioOptimatics	A102
BRCA2	B066
BRCAness	B139
C	
CD4 T cells	B110
CA19-9	A052
cachexia	A119
Cachexia	A108, A128
Cachexia, Antibody Therapy	A110
CAF	A013, B008
CAFs	B024
cAMP, AMPK, PDE	A065
cancer associated fibroblasts	B010
Cancer associated fibroblasts	B003
Cancer Associated Fibroblasts	A018
cancer biology	A057
Cancer cachexia	A120
Cancer cell fitness	A030
Cancer immune evasion	B089
cancer immunology	B097
Cancer Modeling	A001
cancer specific serum biomarker	A088
Cancer stem cells	A040
Cancer-associated cachexia	A117




cancer-associated fibroblast	B018
Cancer-associated fibroblast	A008, B092
Cancer-associated Fibroblast	B019
Cancer-associated fibroblasts	B001
Cancer-assoicated fibroblasts	A019
CAR T cell therapy	B104
CAR T cells, logic-gated, interleukin-12 (IL-12)	A126
CAR T therapy	B085
CAR T-cell	A102
CAR-NKT	B100
Cathepsin S	A084
CD4 T cells	B084
CD73-adenosine signaling	B070
CD8+ T cells	A121
CDK12	B094
CDK9	B043
Cell Signaling	A005
Cell-cell communication	B076
Cell-free RNA	B033
Cell-state-specific MAPK reactivation	B057
Cellular immunotherapy	A103
Cellular Plasticity	A024
Characterization, CAFs, RAS inhibition	A003
Chemokines, PDAC, ACKRs,	B079
chemoresistance	B041
Chemoresistance	A024, B054, B066
chemotherapy	A056, B015, B053
Chemotherapy	B135
Chemotherapy	B137
chemotherapy resistance	A064
chemotherapy TAMs NLRP3	A011
chemotherapy utilization	A137
Cholesterol	A114
Chromatin accessibility	A107
Chronic Pancreatitis	A079
Circulating tumor DNA (ctDNA)	A142



classical-to-basal transition	A059
CLDN18.2, pancreatic adenocarcinoma (PDAC) , KRAS	A044
Clinical Trials	A125
Clonal Heterogeneity	B030
c-MYC	B126
Co-culture	B021
Co-cultures	B108
Collagen	B001
Combination strategy	B040
combination therapy	B049, B122
Combination Therapy	A115
Combinations	B073
Computational biology	A100
computational pathology	A106
conserved SKF activation	B057
copper transporter	A060
Coronin 1C	A020
ctDNA	A042
CTLs	B007
culturomics	B082
Cuproptosis	B055
CXCR4	B108
cytomegalovirus	B093
D	
Daraxonrasib	A139
Deep Cyclic Inhibition	A134
Deep learning	A082
Detection	A076
Diet	A118
Digital Pathology	A090
Discrete Cosine Transform	A069
Disparities	A124
DKK1	A034
DR5	B144



DRP1	A012
Drug Conjugate	A131
drug repurposing	A016
Drug Repurposing	B129
Drug Resistance	A037
Drug screen	B055
E	
early detection	A097, B005
Early detection	A123
Early Detection	A083, A086, A095
early detection of cancer	A089
Early lesions	A005
early phase clinical trial	A133
Early-onset pancreatic cancer	A087
effector CD4	B119
EGFR/ERK, p38/LIF signaling, transcriptome	A051
electronic health records	A072
EMT	A027, A058
ENA splicing	B050
ENACT	A132
engineered models	B013
enhancer reprogramming	A094
epigenetics	B010
Epigenetics	B014, B021
Epithelial-to-mesenchymal plasticity (EMP)	A107
Epitranscriptomics	B117
ERK1	B050
E-selectin	A052
evolutionary bottleneck	A035
External Control Arm	A125
extracellular matrix	B018
Extracellular matrix stiffness	A017
extrafollicular	B077
ex-vivo 3d models	A065
EZH2	B061




F

familial pancreatic cancer	B036
FAS	B116
FASN	A063, B048
Ferroptosis	B089, B121
FGFR	B049
Fibroblast Activation Protein	A131
fibroblasts, immune suppression, tumor microenvironment	B011
fibrosis	A062
Fibrosis	B133
first-in-human trial	A130
FMT, Pancreatic Cancer, phase0 trial	A122
focal adhesion signaling	B044
FOLFIRINOX chemotherapy	A035
FOLFOX	B135
Food Swamps	A138
Functional precision medicine	A070

G

Gangliosides	A033
GDF-15	A108
Gemcitabine	A112
Gemcitabine, Paclitaxel, FOLFIRINOX	B128
gene discovery	B036
Gene expression profiling	A068
genome-wide association study	A101
Genomic biomarkers	A066
Genomics	B034
germinal center	B077
germline susceptibility	B036
Gland	B029
GLP-1; PDAC; GEMM	A055
Glycan	A096
Glycans	A033




Glyco-Oncology	B124
Glycoprotein, Egfr, antigen-presenting cancer-associated fibroblasts (apCAFs)	B023
Gnas	A049
GNAS	A045
Gut Barrier Integrity, Tight junction Proteins, TRAEs	B128

H

Hedgehog signaling	A129
high-content imaging	B042
Histologic subtypes	A143
Histotripsy	B109
HLA-A*02, mesothelin, loss of heterozygosity (LOH)	A126
HMGA2, basal-like, IL1A, pancreatic cancer	B011
HSF1	A060, A114
Human Aging	A090
Human donor pancreas atlas	A093
Hyaluronic acid	A009
Hybrid EMT	A033
Hypoxia	B083
Hypoxia, Enzyme-loaded Microcapsules	B120

I


IL21 mimetic	B110
IGFBP-3, Skeletal Muscle Wasting, Pancreatic Cancer	A110
IgG	B004
IL1	A119
IL-17/IL-17RA Signaling	B102
IL-33	A049, B062
Immune aggregates	B032
Immune checkpoint blockade	B054, B096
Immune escape, HLA loss, immunotherapy	B028
immune evasion	B099
Immune evasion	B101
Immune exclusion	A020
Immunesuppression	B006



immunity	B093
immunocompetent mouse model	B086
Immunogenic Cell Death	B121
immunology	B114
Immunology	B087
Immunomodulation	B120
Immunopectidomics	B095
immunosuppression	A057
Immunosuppression	B082
immunosuppressive profile	B019
immunotherapy	A130, B053, B081, B084, B094
Immunotherapy	B075, B083, B090, B116
Impact	A136
In vitro diagnostics	A081
in vitro model	B078
Inflammation	A021
Injectable nanoparticle-loaded hydrogel	B138
Innate immune signaling	A038
innate immunity	B015
innervation	B020
interception	A092
Interleukin-1 Receptor Accessory Protein	B103
intermediate cell state	A025
Intestinal stem cells (ISCs)	B102
Intraductal Papillary Mucinous Neoplasm (IPMN)	A078
Intraductal papillary mucinous neoplasms	A100
IPMN	A045, A049
IPMN, CDK4/6i, RASi	A065
Irinotecan	A139
Irreversible electroporation, radiation, combination therapy, pancreatic cancer	B140
Isolated Pulmonary Metastases	A074

J

There were no keywords in this range.




K


KMT2D	A107, B076
Kras	A054
KRAS	A012, A042, A048, A108, A117, B048, B051, B067, B071, B074, B110, B114
KRAS RAS(ON) inhibitor Resistance	B060
KRAS G12D	B073
KRAS G12D degrader	B040
KRAS inhibition	B061, B062
KRAS inhibitors	B122
KRAS mutation	B064
KRAS Resistance	B052
KRAS/MAPK signaling	B065
KRAS/MEK	B069
KRASG12D	B043
KRAS-MAPK signaling	B070
KRASQ61; Gastrointestinal malignancies; Pancreatic cancer; RNA sequencing.	A043

L


Lactate metabolism	B117
Lack of Clinical Equipoise	A125
Late-onset pancreatic cancer	A087
LDLR	A114
LINE-1 retrotransposon	A038
Lineage heterogeneity	A040
lipid nanoparticles	B134
lipids	B051
Liposome	B129
Liquid biopsy	A077, A104, B033
Liquid Biopsy	A083, B045
Listeria	A130
Liver metastasis	A052
LLM	A099
Loss of Y	A027
Ly6D	B141



LyP-1	B130
LYPD3	A031
M	
m6Am	B117
Machine learning	A021
Machine Learning	A073
Macrophages	B014, B083
macropinocytosis	A047
MAPS screening platform	B143
Mast cells	B112
MAT2A inhibitor	B132
mdsc	A002
MEIS2	A068
MEK	A134
MEK/ERK signaling	B041
Mesothelin-targeted CAR	B086
Metabolic reprogramming	A116
Metabolic trajectory	A087
metabolism	B051
Metabolism	A013, A111, A115, A118
Metaplasia	A054
metastasis	A027, B031
Metastasis	A009
Metastasis	A058
Metastatic plasticity	A038
Methylation	A026
MICAL2	A054
microbiome	B088
Microbiome	B035, B082
Microenvironment	A005
Micro-farming	A138
mitochondrial	B056
Mitochondrial metabolism	A116
mitotic catastrophe	B094
Molecular glue Pan-RAS(ON) inhibitor	B132



Molecular subtyping	B045
Monitoring	A077
Monoclonal antibody treatments	B141
Monoclonal Therapy	A014
MRTX1133	B048
MT1-MMP	A088
MTA-cooperative PRMT5 inhibitor	B039, B132
MTAP-deleted solid tumors	B039
MUC16	B144
Multiomics	B035
Multiple Instance Learning	A069
Multiplexed mRNA immunotherapy	B106
multi-RAS inhibitor	B047
muscle	A119
mutant GNAS	B062
mutant-p53	A056
MYBL2	B099
MYC	A031, A036, A059, A120, B069
MYC, PDAC, Transcription	B127
MYC-driven classical-to-basal transition	B030
Myeloid	B116
myeloid cells	B031
myofibroblast	B020
N	
Natural Killer Cells	B090
NEIL2	A050
neoadjuvant therapy	B038
neoadjuvant therapy	B037
neuMDSC	B066
neuroendocrine	A135
Neutrophil Chemotaxis	B103
neutrophils	B080
New-onset diabetes (NOD)	A123
NFκB signaling	B101
NLRP3	B066




Non linear Optical Imaging	B017
novel therapeutics	B097
NSQIP	A113
Nutrition, Pancreaticoduodenectomy	A113

O


obesity	A080
olfactory receptor 1A1	A101
Oligometastatic	B131
Oncolytic virotherapy	A004
opioid	B018
Organ dysfunction	A124
Organiods	B127
organoid	B072
Organoid	B078
Organoid Modeling	B052
Organoids	A036, A140, B108
Organotypic Slice Culture	B123
Orthotopic and metastatic pancreatic cancer	B100
OSMR	B123
Overcome DXd/KRAS Inhibitor Resistance	B142

P


PanIN to PDAC	A094
PDAC liver metastasis	A007
p38/IL1A/NFkB/STAT3	B006
p53	A023, A032
Pancreatic cancer	A034
pancreas	A080
Pancreas	A132
pancreas-specific TCR	B119
pancreatic adenocarcinoma	A137
Pancreatic adenocarcinoma	A045
Pancreatic Adenocarcinoma	B121
pancreatic cancer	A016, A097, A141, B015, B044, B084



Pancreatic cancer	A004, A009, A060, A063, A071, A082, B007, B061, B131
Pancreatic Cancer	A001, A073, A074, A095, A102, A138, B004, B091, B102, B109, B120, B123
Pancreatic cancer incidence trends	A143
Pancreatic cancer patient-derived tumoroids	B042
Pancreatic cancer, age-period-cohort analysis	A143
Pancreatic Cancer, KRASG12D Inhibitors, Molecular Docking	B136
Pancreatic Cystic Lesions (PCLs)	A078
pancreatic ductal adenocarcinoma	A025, A106, B047, B072
Pancreatic ductal adenocarcinoma	A019, A040, A066, A072, A091, A101, A103, B016, B050, B090, B124, B138
Pancreatic Ductal Adenocarcinoma	A069, B035, B070
Pancreatic ductal adenocarcinoma	B071
Pancreatic ductal adenocarcinoma (PDAC)	A039, A142, B065, B112
Pancreatic Ductal Adenocarcinoma (PDAC)	A078, B126, B130
Pancreatic ductal adenocarcinoma (PDAC), Tumor microenvironment (TME), CA19-9	B023
Pancreatic ductal adenocarcinoma (PDAC), tumor progression, CREB1	A051
Pancreatic ductal adenocarcinoma, RAS inhibitor, RNA splicing	B058
Pancreatic intraepithelial neoplasia	A091
Pancreatic Morphology	A086
Pancreatic precursor lesions	A093
Pancreatic stellate cells	A017
PanIN	A090
PanIN progression	B013
PanIN, precancer	A092
Pan-KRAS inhibitors	B046
Pan-RAS inhibition	B012
Pan-RASi Dual-Payload ADC	B142
PARP Inhibition	B139
Patient derived organoids	A079
patient derived tumor organoid	B074



patient stratification	A064
patient-derived models	A035
Patient-derived organoid	A008
Patient-derived toroid	B060
PDAC	A006, A127, A128, B014, B020, B024, B039, B064, B067, B068, B075, B105, B113, B143
PDAC subtype	A026
PDAC subtyping	A104
PDAC targeted immunotherapy	B095
PDAC, CAFs, normal fibroblasts,	A003
PDAC, epigenetics, cell state, single-cell sequencing	A029
PDAC, IPMN, CAF	B021
Peer-review	A136
Peptide delivery, Immunotherapy,	B107
Perineural invasion	B003, B009, B138
Personalized medicine	A070
pharmacophenotypic analysis	B042
photomedicine	B134
plasticity	A023
plectin	B097
Post-operative, complications	A113
Precancer	A096
precision medicine	A141
Precision Medicine	A067, A140
Precision Medicine	B052
precision population cancer care	A141
precursor cells	A032
prediction algorithm	A089
Predictive Modeling	A073
Premalignant lesions	A034
Pre-metastatic liver	B105
Prognosis	A021
Prognostic biomarker	A068
prognostic biomarkers	A106
Proliferation	B137




Prospective screening study	A081
proteases	A084
protein degradation	B059
proteolytic cleavage fragment	A088
Proteomics	A111, B109
Proton beam therapy	B131
PSC activation	A006
Pyrimidine	A112

Q


There were no keywords in this range.

R

Radiomics	A086
RAS	A047, B068
RAS inhibition	B008, B054, B059, B087, B101, B104
RAS inhibition resistance	B072
RAS inhibitor	B063, B095, B118
RAS inhibitor resistance	A041, B044
Ras inhibitors	B025
RAS inhibitors	A070
RAS inhibitors and IL1 targeting	B011
RAS maturation	B056
RAS(ON) inhibition	B053, B073
Real-world data	A142
real-world outcomes	A137
Regulatory T cells	B092
Replication stress	A127
resistance	B063
Resistance	B043, B066, B137
Resistance mechanism	B040
risk prediction	A072
RNA	A076
RNA binding protein	A053
RNA polymerase II	A050
ROCK2	B133




RTK-RAS	A067
RUNX1/2	B010
S	
schedule-dependent treatment optimization	B122
Scientific merit	A136
screening program	A089
secretome	A056
Senescence	B024
SFK	B068
SHP2	A118
Single cell RNAseq	B105
Single Cell Transcriptomics	B066
single cell, genomics, spatial	B028
single-cell and spatial transcriptomics	B030
Single-cell spatial transcriptomics	A091
Single-cell/spatial transcriptomics	B096
Skeletal muscle wasting	A120
small molecule inhibitor	B074
SOAT1	B056
Somatic genomic profiling	A066
spatial	A080
Spatial	B029
Spatial biology	B027
Spatial immunophenotyping	B032
Spatial multi-omics	A007, A071, A100
spatial proteomics	B031
Spatial proteomics	B032, B034
Spatial transcriptomics	A093, B009
Spatial Transcriptomics	B025
Spatial transcriptomics and proteomics	B026
spatial whole-transcriptomic	A061
stat3	A002
STAT5	B113
stem-like T cells	B085
stereotactic ablative radiotherapy	B038




stiffness	B008
Stiffness	A046
STORM microscopy	A046
Stroma	B001, B007
Stromal reprogramming	A006
subtype specification	A053
Subtyping	A037
SUMOylation	A139
Surgical conversion	B038
survival rate	A135
Survival, Chemotherapy, Urolithin A	B128
Synergistic priming	A129
Synergy	B055
Systemic Inflammation	A117

T


Topoisomerase II	A121
T cell	B093
T cell exclusion	B047
T cell exhaustion	B115
T Cell Immunity	B012
T cell manufacturing	B085
T cell receptor	B078
T cells	B087
Tandem CARs	B091
targeted therapy	A062
Tbox inhibition	B129
T-cell signaling	B113
Tertiary Lymphoid Structures	A018
TFEB	B041
TGFb/Smad 2	B141
TGF-beta	A048
TGF-β signaling	A020
Th1	B092
therapeutic response	B037
Therapeutic Target	B103



Therapeutic, Xenografts, Dual Energy X-ray Absorptiometry	A110
Therapeutics	A115
Therapeutics	A140
Therapy response	A071, B045
Third-line treatment	B135
TME	B029
tnf	A002
TPL2	B099
transcription factors	A094
Transcriptional plasticity	A030
Transcriptional response	B067
Transcription–replication conflicts	A050
Transcriptomic heterogeneity	A028
Transcriptomic profiling	A103
Transcriptomics	A048
Translational research	B003
Treatment resistance	B033
Treatment selection	A105
Trial eligibility	A124
TSHZ2	A025
Tumor architecture	B027
tumor associated macrophages	A062
Tumor associated macrophages	B016
Tumor cell plasticity	A007
Tumor Cell Plasticity	A037
tumor crosstalk	A061
Tumor ecosystem	B025
tumor evolution	A023
Tumor Heterogeneity	A024
Tumor Heterogeneity, Antigen Escape	B091
Tumor immune microenvironment	A039, A116
tumor immunity	B088
tumor immunology	B080
Tumor immunology	B076
tumor initiation	A032



tumor interstitial fluid	B005
Tumor micornevironment	B114
tumor microenvironment	A016, A061, B005, B013, B016, B037, B080
Tumor microenvironment	A008, A017, A019, A028, A063, A129, B004, B096, B112
Tumor Microenvironment	A001, A004, A014, A046, A131, B017
tumor microenvironment	A012
Tumor microenvironment	A030, B019, B115
Tumor Microenvironment	B012
Tumor microenvironment (TME)	A051
Tumor Microenvironment (TME) Remodeling	B124
Tumor Microenvironment-Activated	B142
Tumor penetrating peptides	B075
Tumor Treating Fields	B071
Tumor-associated antigens	B106
Tumor-Homing Peptides	B130
Tumor-infiltrating lymphocyte	B115
Tumor-targeted lipid nanoparticles	B106
Tumour heterogeneity	A039
Tumour, Immune, Stroma	B034
U	
UNC5B	A058
urinary metabolomics	A109
Urine	A083
urine miRNA	A085
USP36	B126
V	
vaccine	B081
Vaccine	B118
W	
wearable technology	A098
Wiki	A099



Wild-Type IDH1 (wtIDH1)	B139
window of opportunity trial	B069
wound healing	A057

X

xCT	B064
-----	------

Y

There were no keywords in this range.

Z

There were no keywords in this range.